Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio


NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.

Read this article:
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

Related Posts